Payment overview · 2025
General Payments
$101.33
6 reported records · 6 companies
Healthcare provider profile · identity verified
Alexander William Filipski, DO
Allopathic & Osteopathic Physicians|Family Medicine · OSWEGO, NY · NPI 1598056202
Verified facts
What the public records show
CMS Open Payments records show Alexander William Filipski, DO received $101.33 in general payments during 2025 across 6 reported records.
Braeburn Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Sublocade, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Sublocade by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Braeburn Inc. | Unresolved — no canonical attribution shown | $19.62 | 19.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.70 | 18.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.93 | 17.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.48 | 15.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.02 | 14.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.58 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.33 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 100 |
| Lisinopril | Lisinopril | 310 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 52 |
| Omeprazole | Omeprazole | 225 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 42 |
| Gabapentin | Gabapentin | 188 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 35 |
| Trulicity | Dulaglutide | 150 | 25 |
| Famotidine | Famotidine | 147 | 31 |
| Metformin Hcl | Metformin Hcl | 133 | 42 |
| Jardiance | Empagliflozin | 119 | 24 |
| Metformin Hcl Er | Metformin Hcl | 113 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 16 |
| Losartan Potassium | Losartan Potassium | 92 | 27 |
| Glipizide Er | Glipizide | 88 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 88 | 13 |
| Sertraline Hcl | Sertraline Hcl | 86 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 15 |
| Trazodone Hcl | Trazodone Hcl | 83 | 14 |
| Buspirone Hcl | Buspirone Hcl | 82 | 23 |
| Meloxicam | Meloxicam | 77 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 21 |
| Carvedilol | Carvedilol | 74 | 13 |
| Prednisone | Prednisone | 73 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 17 |
| Eliquis | Apixaban | 68 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 25 |
| Bupropion Xl | Bupropion Hcl | 60 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 19 |
| Allopurinol | Allopurinol | 56 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 14 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Ozempic | Semaglutide | 51 | 11 |
| Celecoxib | Celecoxib | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 28 |
| Furosemide | Furosemide | 41 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 12 |
| Topiramate | Topiramate | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 20 |
| Alprazolam | Alprazolam | 37 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 16 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Simvastatin | Simvastatin | 29 | 11 |
| Tradjenta | Linagliptin | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sublocade | Buprenorphine | 13 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Calcitriol | Calcitriol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.33 · 6 records | Braeburn Inc. | AIRSUPRA, BRIXADI, NURTEC ODT, SUBLOCADE, TRELEGY ELLIPTA, ZAVZPRET, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Sublocade play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error